| Melanie A Klawiter, | |
|
200 Commons Way Ste C, Kalispell, MT 59901-1915 | |
| (406) 752-5095 | |
| Not Available |
| Full Name | Melanie A Klawiter |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 18 Years |
| Location | 200 Commons Way Ste C, Kalispell, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164630547 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | R-7885 (Iowa) | Secondary |
| 2084N0400X | Psychiatry & Neurology - Neurology | 12423 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kalispell Regional Medical Center | Kalispell, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kalispell Regional Medical Center Inc | 5294644381 | 354 |
News Archive
...and efforts to establish a new system to track adverse drug events have been delayed by at least four years, according to a November 2006 report commissioned by the agency, the Wall Street Journal reports.
A World Health Organization (WHO) and Republic of Korea project to improve the health of women and children in the Democratic People's Republic of Korea (DPRK) continues into its second year. The US$ 20 million project, funded by the Republic of Korea, will benefit five million people in the DPR Korea.
Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced the publication of preclinical data showing the company's dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise as a treatment for chronic lymphocytic leukemia.
"The lives of more than 740,000 people in nine African countries were saved between 2004 and 2008 by the U.S. President's Emergency Plan for AIDS Relief [PEPFAR]," according to a study conducted by Stanford University School of Medicine researchers and published in the Journal of the American Medical Association (JAMA) on Wednesday, HealthDay News reports.
Net sales for the second quarter of fiscal 2010 were $31,147,000 as compared to $33,280,000 for the same period of the prior fiscal year, a decrease of 6%. Net earnings for the second quarter of fiscal 2010 were $5,980,000 or $0.15 per diluted share, decreases of 18% and 17%, respectively, compared to the second quarter of fiscal 2009. Diluted common shares outstanding for fiscal 2010 and 2009 were 41,177,000 and 41,133,000, respectively.
› Verified 8 days ago
| Entity Name | Kalispell Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235333139 PECOS PAC ID: 5294644381 Enrollment ID: O20031122000142 |
News Archive
...and efforts to establish a new system to track adverse drug events have been delayed by at least four years, according to a November 2006 report commissioned by the agency, the Wall Street Journal reports.
A World Health Organization (WHO) and Republic of Korea project to improve the health of women and children in the Democratic People's Republic of Korea (DPRK) continues into its second year. The US$ 20 million project, funded by the Republic of Korea, will benefit five million people in the DPR Korea.
Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced the publication of preclinical data showing the company's dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise as a treatment for chronic lymphocytic leukemia.
"The lives of more than 740,000 people in nine African countries were saved between 2004 and 2008 by the U.S. President's Emergency Plan for AIDS Relief [PEPFAR]," according to a study conducted by Stanford University School of Medicine researchers and published in the Journal of the American Medical Association (JAMA) on Wednesday, HealthDay News reports.
Net sales for the second quarter of fiscal 2010 were $31,147,000 as compared to $33,280,000 for the same period of the prior fiscal year, a decrease of 6%. Net earnings for the second quarter of fiscal 2010 were $5,980,000 or $0.15 per diluted share, decreases of 18% and 17%, respectively, compared to the second quarter of fiscal 2009. Diluted common shares outstanding for fiscal 2010 and 2009 were 41,177,000 and 41,133,000, respectively.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melanie A Klawiter, 200 Commons Way Ste C, Kalispell, MT 59901-1915 Ph: (406) 752-5095 | Melanie A Klawiter, 200 Commons Way Ste C, Kalispell, MT 59901-1915 Ph: (406) 752-5095 |
News Archive
...and efforts to establish a new system to track adverse drug events have been delayed by at least four years, according to a November 2006 report commissioned by the agency, the Wall Street Journal reports.
A World Health Organization (WHO) and Republic of Korea project to improve the health of women and children in the Democratic People's Republic of Korea (DPRK) continues into its second year. The US$ 20 million project, funded by the Republic of Korea, will benefit five million people in the DPR Korea.
Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced the publication of preclinical data showing the company's dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise as a treatment for chronic lymphocytic leukemia.
"The lives of more than 740,000 people in nine African countries were saved between 2004 and 2008 by the U.S. President's Emergency Plan for AIDS Relief [PEPFAR]," according to a study conducted by Stanford University School of Medicine researchers and published in the Journal of the American Medical Association (JAMA) on Wednesday, HealthDay News reports.
Net sales for the second quarter of fiscal 2010 were $31,147,000 as compared to $33,280,000 for the same period of the prior fiscal year, a decrease of 6%. Net earnings for the second quarter of fiscal 2010 were $5,980,000 or $0.15 per diluted share, decreases of 18% and 17%, respectively, compared to the second quarter of fiscal 2009. Diluted common shares outstanding for fiscal 2010 and 2009 were 41,177,000 and 41,133,000, respectively.
› Verified 8 days ago
Joseph Hugh Boyle, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 75 Claremont St, Suite C, Kalispell, MT 59901 Phone: 406-758-5155 | |
Robert D Schimpff, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 202 Conway Dr, Suite 100, Kalispell, MT 59901 Phone: 406-751-5666 Fax: 406-755-0971 | |
Kurt D Lindsay, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 200 Commons Way Ste C, Kalispell, MT 59901 Phone: 406-752-5095 Fax: 406-752-5058 | |
Constance Mash, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 200 Heritage Way, Kalispell, MT 59901 Phone: 406-756-3950 Fax: 406-756-3957 | |
Tanner Ferderer, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 200 Commons Way Ste C, Kalispell, MT 59901 Phone: 406-752-5095 Fax: 406-751-3079 | |
Victor C. Houser Iii, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 355 1st Avenue West N, Kalispell, MT 59901 Phone: 406-755-6200 Fax: 406-755-6208 |